Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Hansa Biopharma Completes Enrolment in Global Pivotal Phase 3 Trial of imlifidase in Anti-Glomerular Basement Membrane Disease

Data from the trial is expected to be shared in 2025Lund, Sweden, 5 December 2024. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA) today announced it has completed the enrolment of patients in the GOOD-IDES-02 trial, a global pivotal Phase 3 trial in anti-glomerular basement membrane (anti-GBM) disease. Anti-GBM is a rare, severe autoimmune condition affecting around 1.6 people per million annually.[1] Imlifidase has been granted orphan drug designation for the treatment of anti-GBM disease by both the U.S. FDA and the European Medicines Agency (EMA). Enrolment completion was originally

Crunchfish announces the last day of trading in BTU

Crunchfish AB ("Crunchfish" or the "Company") announces that the rights issue of units that was announced on September 20th, 2024 (the “Rights Issue”) has been registered with the Swedish Companies Registration Office (Sw. Bolagsverket) and paid subscribed units (Sw. betalda tecknade units, "BTU") will thus be replaced with ordinary shares and warrants of series TO 10 and TO 11. The last day of trading in BTU is December 10th, 2024 and new shares and warrants are expected to be booked into the respective custody/VP account on December 16, 2024. The record date for the conversion from BTU to

LINK Arkitektur - Contract for major expansion of Regionshospitalet Randers

Multiconsult's (Oslo: MULTI) fully owned Danish subsidiary LINK Arkitektur A/S, in collaboration with 5E Byg A/S, has been nominated for the contract for the expansion of Regionshospitalet Randers in Denmark.The project involves the design and construction of 22 000 m² of new treatment and patient facilities, making it one of Denmark’s largest hospital expansion projects. It is delivered under an integrated cooperation model, with a total target price of DKK 745 million. Work will commence in February 2025, with completion expected by the end of 2032. This represents a significant

ITAB signs share purchase agreement for the acquisition of HMY following completion of the information and consultation procedure

ITAB Shop Concept AB (publ) (“ITAB”) has today signed a final and definitive share purchase agreement to acquire Financière HMY (“HMY”) for a cash consideration of EUR 320 million (approximately SEK 3,613 million) on a cash and debt free basis. This follows the completion of an information and consultation procedure with the employee representative body of HMY, in accordance with what was announced by ITAB on 25 September 2024.As announced on 25 September 2024, ITAB had previously granted a binding put option to the shareholders of HMY by which ITAB agreed to acquire 100 per cent of the

Getinge opens new Experience Center in India

Getinge is opening a new Experience Center in Mumbai, India. The facility recreates real-world healthcare settings to bring customers and other visitors the opportunity to assess how innovations can improve healthcare delivery and efficiency. Getinge’s new Experience Center in Mumbai, India, showcases the medtech company’s innovative solutions, including the cutting-edge Getinge IN2 OR Modular Room System, a transformative technology designed to meet the evolving needs of modern surgery. The system is engineered to offer flexibility, efficiency, and cost-effectiveness, addressing

Liquid Wind and SAMSUNG E&A partner to accelerate the development of eFuel facilities

Liquid Wind and SAMSUNG E&A announce the entering into a collaboration agreement to accelerate the development of eFuel facilities outside of Europe, in Asia, Africa, and the Middle East. The partnership aims to combine each party’s expertise to evaluate opportunities for collaboration in eFuel facility development, extending Liquid Wind’s reach and ongoing business development. Claes Fredriksson, CEO and founder Liquid Wind. In Kyo Cheong, Minister for Trade, Industry and Energy. Hong Namkoong, President and CEO of SAMSUNG E&A. Under the collaboration, SAMSUNG E&A may be

Form 8.3 - Britvic plc

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1.         KEY INFORMATION (a) Full name of discloser: Magnetar Capital Partners LP(b) Owner or controller of interests and shortpositions disclosed, if different from 1(a):    The naming of nominee or vehicle companies isinsufficient.  For a trust, the trustee(s),settlor and beneficiaries must be named.(c) Name of offeror/offeree in relation to whose Britvic plc

Raisio plc's Research Foundation awarded 2025 postgraduate scholarships

Press release, December 5, 2024 At its meeting held on November 25, 2024, the Board of Directors of Raisio plc Research Foundation (Foundation) has decided to award a total of EUR 152 500 in post graduate research grants for 2025. The research grant of the Research Foundation is intended as a salary grant for a doctoral researcher. A doctoral researcher whose PhD topic has been awarded with a research grant of the Foundation has the opportunity to receive a salary grant for a maximum of four years, provided that the doctoral studies proceed according to plans. The maximal duration of

BioGaia launches a new probiotic supplement, BioGaia® Gastrus® PURE ACTION, designed for people with sensitive digestive systems

We are proud to launch BioGaia® Gastrus® PURE ACTION, a clean ingredient, double-strength, FODMAP-friendly probiotic designed to support individuals with sensitive stomachs. This latest addition to BioGaia’s product portfolio in adult gut health expands access to specialized advanced, evidence-based solutions for improved digestive health and quality of life. BioGaia® Gastrus® PURE ACTION is formulated with the proprietary, patented probiotic strains L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475, carefully selected for their clinically proven efficacy in managing digestive issues and

Heimdal Announces New Partnership with ITHealth to Reinforce Cyber Security for NHS Organisations

LONDON, United Kingdom, 5 December 2024 - Heimdal, a global leader in proactive cyber security solutions, announces a new partnership with ITHealth, a trusted cyber security provider to the NHS. This partnership expands ITHealth’s offerings by integrating Heimdal’s advanced capabilities into the ITHealth Dashboard.By combining Heimdal’s threat protection and mitigation features with the ITHealth Dashboard, NHS organisations can improve security operations and build greater resilience.  Heimdal’s solutions are trusted by over 16,000 organisations worldwide, providing clear threat

National award for Teesside University building

A state-of-the art Teesside University science facility providing cutting edge training to the next generation of health and medical professionals has received a prestigious national award. The University achieved a memorable hat-trick at the Constructing Excellence National Awards, scooping building project of the year and two highly commended awards. BIOS, a £36.9m building for teaching science, health and medical subjects, was awarded the Building Project of the Year Award, as well as Highly Commended in the Integration & Collaborative Working category. The building was

Form 8.3 - Direct Line Insurance Group Plc

FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”)   1. KEY INFORMATION   +----------------------------------------------+-------------------------------+|(a) Full name of discloser: |Ninety One UK Ltd |+----------------------------------------------+-------------------------------+|(b) Owner or controller of interests and short|  ||positions disclosed, if different from

Form 8.3 - Aviva Plc

FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”)   1. KEY INFORMATION   +----------------------------------------+-------------------------------------+|(a) Full name of discloser: |Ninety One UK Ltd |+----------------------------------------+-------------------------------------+|(b) Owner or controller of interests and|  ||short positions disclosed, if different

Lundbeck highlights commitment to the rare epilepsy community at American Epilepsy Society (AES) Annual Meeting with data presentations

Longboard Pharmaceuticals, now a wholly owned subsidiary of Lundbeck, presents scientific data in multiple poster presentations showcasing the potential of bexicaserin in Developmental and Epileptic Encephalopathies (DEEs) at the American Epilepsy Society (AES) Annual Meeting in Los Angeles, U.S.H. Lundbeck A/S (Lundbeck) today announced that data will be presented for bexicaserin, a novel, highly selective investigational potential treatment in development for seizures associated with Developmental and Epileptic Encephalopathies (DEEs), in poster sessions at the 2024 AES Annual Meeting.

Safello enters into agreement with liquidity provider B2C2 to enhance liquidity for trading services

Stockholm, 5 December, 2024 | Safello, the leading cryptocurrency exchange in the Nordics, has entered into an agreement with B2C2, a global leader in the institutional trading of digital assets, to provide deeper liquidity across its platform. The partnership enables Safello to leverage B2C2’s advanced liquidity technology, offering improved trade execution, competitive pricing, and efficient market access, which are important preparatory steps for Safello to expand its service offerings with additional order types. By tapping into B2C2’s liquidity, Safello can maintain strong pricing

Oncoinvent ASA announces oversubscribed private placement

Oncoinvent ASA ("Oncoinvent" or the "Company") is pleased to announce that it has today successfully completed the bookbuilding process for a private placement of new shares and that gross proceeds of NOK 130 million is being raised by the issuance of 65,000,000 new shares (the "Offer Shares") at a subscription price of NOK 2 per share (the "Private Placement").“We are pleased to announce the successful completion of the private placement with a contemplated subsequent listing on Euronext Growth Oslo. I would like to express my gratitude for shareholders' full support and trust in our

BPC Instruments receives orders from US bioenergy firm valued at 1.1 MSEK

BPC Instruments AB (publ) ("BPC") announces two consecutive purchase orders from a leading US bioenergy firm. The orders include the delivery of several instruments, including two AMPTS[®] III systems, with a combined value of approximately 1.1 MSEK. The client is replacing its entire setup for BMP tests based on manometric measurements with BPC's systems for both batch and continuous operation.CEO Dr. Jing Liu comments: "We are proud to collaborate with a leading player in the US as they continue to drive progress in RNG development, scale up renewable energy production, and expand

COP29: Future-proofing Food Production via a Proven Business Case

300% more food, 80% water saved, higher profitability for the farmer The urgency to transform the agri-food systems is clear from discussions and negotiations at COP and previous climate conferences. Now, there’s a proven business case for it.At COP29, Spowdi presented a proven business case resulting in 300% more food, 80% water saved and higher profitability for the small-hold farmer. Here are the highlights from the transforming food systems discussion “A Proven Business Case: 300% More Food” held at the Swedish Pavilion during COP29 in Baku. The situation as we know it:

Biosergen resolves on a compensation issue to underwriters in connection with the completed exercise period for warrants of series TO3

The exercise period for Biosergen AB (”Biosergen” or the "Company") warrants of series TO3 (the "Warrants") was completed on November 29, 2024. In accordance with the underwriting agreements entered into in connection with the exercise of the Warrants, the Board of Directors has today, on December 5, 2024, relying on the authorization from the Annual General Meeting on June 14, 2024, resolved on a directed issue of 734,963 shares to such underwriters in the warrant program who have chosen to receive underwriting compensation in the form of newly issued shares in the Company (the "Compensation

Circio Holding ASA – Exercise of Warrants by primary insider CEO Erik D Wiklund

Oslo, Norway 5 December 2024, Circio Holding ASA (OSE: CRNA) Reference is made to the stock exchange announcement on 4 December 2024 regarding commencement of the exercise period for Warrants from 4-18 December 2024 (the "Exercise Period"). Erik Digman Wiklund, CEO of Circio, has on 5 December 2024 exercised a total of 140,400 Warrants, for the allocation of 140,400 New Shares in the Company at a price per New Share of NOK 0.60. This represents all of the Warrants issued to Erik Digman Wiklund in connection with the Rights Issue completed in July 2024. A total of 13,864,852 warrants (

Nominated for significant framework agreements with The Norwegian Defence Estates Agency

Multiconsult (OSE: MULTI)Multiconsult Norge AS, with LINK Arkitektur AS and LPO Arkitekter AS as subcontractors, has been nominated for leading positions in the R01666 framework agreement for design and consulting services with the Norwegian Defence Estates Agency (NDEA) (Forsvarsbygg). NDEA will enter into parallel framework agreements for six geographic areas, with up to three suppliers per area. The total estimated value of the agreement is NOK 1.5 billion excluding VAT, covering a range of multidisciplinary projects.Multiconsult has been nominated for first place in Øst (NOK 450

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 264 – 5 DECEMBER 2024   In connection with the announced share buy-back program in NORDEN, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcements nos. 235/24 and 237/24.   Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Therese Möllevinge, Head of Investor Relations, tel.: +45 41 37 16 38, e-mail: thm@norden.com Isabella Zaugg Hansen, Investor Relations Manager, tel.: +45 27 62 90 96, e-mail: izh@norden.com

Salipro Biotech Expands Global Intellectual Property Portfolio with Granted Patents in Australia and Singapore

Salipro Biotech strengthens its global intellectual property portfolio with granted patents in Singapore and Australia, protecting its proprietary Salipro[®] platform technology to enable the development of therapeutics against challenging drug targets.Stockholm, Sweden, December 5, 2024 – Salipro Biotech AB, a Swedish biotechnology company focused on advancing drug discovery for challenging drug targets, today announced the issuance of granted patents in both Singapore and Australia for its Salipro[®] platform technology, a novel and proprietary method for directly isolating and purifying

There are no items matching the current filter
There are no more items matching the current filter
Back to top